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Introduction {#jdi12139-sec-0005}
============

Compared with non‐diabetic individuals, people with type 2 diabetes are at increased risk of developing non‐alcoholic fatty liver disease (NAFLD), and have a higher risk of developing fibrosis and cirrhosis[1](#jdi12139-bib-0001 jdi12139-bib-0002 jdi12139-bib-0003){ref-type="ref"}. NAFLD affects 30% of the general adult population, and 60--80% of diabetic and obese patients[4](#jdi12139-bib-0004 jdi12139-bib-0005){ref-type="ref"}. There is now growing evidence that NAFLD, especially in patients with type 2 diabetes, could be linked to an increased risk of developing cardiovascular disease (CVD) independently of other known risk factors[6](#jdi12139-bib-0006 jdi12139-bib-0007 jdi12139-bib-0008 jdi12139-bib-0009 jdi12139-bib-0010){ref-type="ref"}. In contrast, there is currently very little information on the association between NAFLD and chronic microvascular complications, such as retinopathy, nephropathy and neuropathy, in people with type 2 diabetes. To date, only a few studies have reported that NAFLD is independently associated with diabetic retinopathy or nephropathy[11](#jdi12139-bib-0011 jdi12139-bib-0012 jdi12139-bib-0013){ref-type="ref"}. We have assessed whether NAFLD, as diagnosed by ultrasonography, is associated with an increased risk of macrovascular (cerebrovascular disease, coronary artery disease and peripheral arterial disease) and microvascular complications (retinopathy, nephropathy and peripheral polyneuropathy) in a clinical cohort of Korean patients with type 2 diabetes.

Materials and Methods {#jdi12139-sec-0006}
=====================

Participants {#jdi12139-sec-0007}
------------

Data for Korean patients with type 2 diabetes who visited the diabetes clinic at Soonchunhyang University Bucheon Hospital during 2001--2008 were analyzed retrospectively. All patients (*n* = 1,410) who had undergone thorough evaluation for diabetic complications, with regular follow up for more than 2 years, were enrolled. The following patients were excluded: (i) patients (*n* = 378) for whom liver ultrasonography was not carried out, or not available; and (ii) patients (*n* = 103) with any clinical evidence of cirrhosis or other causes of chronic liver disease (i.e., alcohol intake \>20 g/day, viral hepatitis, autoimmune hepatitis, hemochromatosis and use of hepatotoxic medications). The remaining 929 patients with type 2 diabetes were included in the final analysis. The present study was approved by the institutional review board of Soonchunhyang University Bucheon Hospital.

Measurements {#jdi12139-sec-0008}
------------

Fasting and postprandial 2‐h glucose and C‐peptide levels, glycated hemoglobin (HbA1c), total cholesterol, triglyceride, high‐density lipoprotein (HDL) cholesterol, low‐density lipoprotein (LDL) cholesterol, serum creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma‐glutamyl transferase (GGT) and high‐sensitivity C‐reactive protein (hs‐CRP) were measured. HbA1c was measured by ion‐exchange high‐performance liquid chromatography (Bio‐Rad, Hercules, CA, USA). The reported values are the mean of the nearest three determinations around the time of evaluation for complications. Serum C‐peptide level was determined by immunoradiometric assay (Immunotech, Prague, Czech Republic). Delta C‐peptide was defined as postprandial serum C‐peptide minus fasting C‐peptide level. Homeostasis model assessment insulin resistance index (HOMA‐IR) was calculated as follows:

HOMA‐IR = fasting plasma glucose (mmol/L) × fasting serum insulin (uIU/mL)/22.5.

Liver ultrasonography was carried out by experienced radiologists. The diagnosis of hepatic steatosis was made on the basis of characteristic sonographic features; that is, diffuse hyperechogenicity of the liver relative to kidneys, ultrasound beam attenuation and poor visualization of intrahepatic structures.

Assessment of Diabetic Complications {#jdi12139-sec-0009}
------------------------------------

Information regarding duration of diabetes, familial history of diabetes mellitus, and previous history of hypertension and macrovascular complications (cerebrovascular disease, coronary artery disease and peripheral arterial disease) was obtained from the patients\' medical records.

Diabetic retinopathy was evaluated by experienced ophthalmologists. If required, fluorescein angiography was carried out. Diabetic nephropathy included microalbuminuria, overt albuminuria and azotemia. Albuminuria was determined by radioimmunoassay (Immunotech) using spot urine or time‐collected urine. Microalbuminuria was defined as an albumin excretion rate of 20--200 μg/min, an albumin‐to‐creatinine ratio in spot urine of 30--300 mg/g or a 24‐h urine protein of 30--300 mg/day. Diabetic neuropathy was diagnosed by nerve conduction velocity testing or the current perception threshold test. Diabetic neuropathy was also established by the presence of typical symptoms and compatible findings on neurological examinations or a history of treatment for neuropathy.

Coronary artery disease was diagnosed based on a patient\'s hospital medical record of myocardial infarction, angina pectoris, coronary artery bypass surgery, percutaneous coronary angioplasty or electrocardiographic changes typical of ischemia (the presence of Q/Qs pattern, significant ST segment depression, or deep T wave inversion). Cerebrovascular disease was defined by the presence of either transient ischemic attack or strokes. Peripheral arterial disease was defined by the presence of ischemic foot ulcers, gangrene, a history of vascular surgery, significant stenosis on angiography or abnormal ankle--brachial index (≤0.9).

Statistical Analysis {#jdi12139-sec-0010}
--------------------

Statistical analyses were carried out using SPSS for Windows 14.0 software (SPSS Inc., Chicago, IL, USA). Results are expressed as the mean ± standard deviation. Variables with a skewed distribution, such as blood concentrations of glucose, triglycerides and HbA1c, were log‐transformed before analysis. Unpaired Student\'s *t*‐tests were used to compare between‐group differences. The χ^2^‐test was used to compare frequencies. Multivariate logistic regression analyses were carried out to estimate the odds ratios (ORs) for diabetic vascular complications after adjusting for other clinical and biochemical variables. A *P*‐value of \<0.05 was deemed to show statistical significance.

Results {#jdi12139-sec-0011}
=======

Overall, the 929 participants of the study had a mean age of 57.7 years, mean body mass index (BMI) of 24.8 kg/m^2^, mean HbA1c of 8.4% and mean duration of diabetes of 6.2 years. The prevalence of NAFLD in the 929 participants of the study was 63.3% (588/929).

The clinical and biochemical characteristics of patients stratified by their NAFLD status are shown in Table [1](#jdi12139-tbl-0001){ref-type="table-wrap"}. Patients with NAFLD were younger, tended to be male, had higher BMI, shorter duration of diabetes, higher prevalence of hypertension, higher total cholesterol, lower HDL cholesterol and higher triglyceride levels than those without NAFLD. Furthermore, fasting and postprandial C‐peptide levels, insulin levels, and HOMA‐IR values were higher in patients with NAFLD than in those without NAFLD. The proportion of insulin users was lower in patients with NAFLD. No significant difference between groups was found in glycemic control, serum AST, ALT, GGT and hs‐CRP concentrations.

###### Baseline characteristics of the type 2 diabetic patients according to non‐alcoholic fatty liver disease status

                                   Without NAFLD (*n* = 341, 36.7%)   With NAFLD (*n* = 588, 63.3%)   *P*‐value
  -------------------------------- ---------------------------------- ------------------------------- -----------
  Age (years)                      59.3 ± 11.9                        56.7 ± 11.7                     0.001
  Sex, male (%)                    48.7                               55.1                            0.034
  Duration of DM (years)           7.2 ± 7.1                          5.6 ± 6.3                       0.001
  BMI (kg/m^2^)                    23.3 ± 3.4                         25.8 ± 3.5                      \<0.001
  HbA1c (%)                        8.3 ± 2.21                         8.4 ± 1.1                       0.782
  SBP (mmHg)                       130.5 ± 19.6                       132.0 ± 18.9                    0.250
  DBP(mmHg)                        76.8 ± 12.7                        78.6 ± 12.1                     0.040
  Hypertension (%)                 60.1                               69.1                            0.004
  Total cholesterol (mg/dL)        190.8 ± 44.1                       202.3 ± 45.3                    \<0.001
  LDL cholesterol (mg/dL)          113.6 ± 42.4                       123.2 ± 48.6                    0.092
  HDL cholesterol (mg/dL)          46.4 ± 11.8                        43.3 ± 10.4                     0.001
  Triglycerides (mg/dL)            157.9 ± 104.3                      209.9 ± 140.8                   \<0.001
  AST (U/I)                        25.1 ± 43.7                        29.2 ± 37.5                     0.141
  ALT (U/I)                        30.1 ± 80.9                        37.9 ± 68.8                     0.119
  GGT (U/I)                        49.2 ± 52.5                        67.5 ± 138.6                    0.102
  hs‐CRP (mg/dL)                   0.84 ± 1.84                        0.60 ± 1.63                     0.129
  HOMA‐IR                          3.3 ± 2.8                          5.0 ± 4.8                       \<0.001
  Fasting C‐peptide (ng/mL)        2.3 ± 1.4                          2.9 ± 1.5                       \<0.001
  Postprandial C‐peptide (ng/mL)   5.7 ± 3.3                          7.3 ± 4.0                       \<0.001
  Fasting insulin (uIU/mL)         8.6 ± 7.4                          12.4 ± 10.4                     \<0.001
  Postprandial insulin (uIU/mL)    30.5 ± 25.9                        46.3 ± 40.9                     \<0.001
  Delta C‐peptide (ng/mL)          2.6 ± 2.0                          4.9 ± 4.5                       \<0.001
  Insulin user (%)                 34.1                               28.7                            0.007
  Oral hypoglycemic agents (%)     55.4                               58.0                            0.532
  Lipid lowering agents (%)        56.9                               55.5                            0.420
  ACEI or ARB (%)                  44.3                               35.3                            0.120

Data are shown as mean ± standard deviation. Delta C‐peptide = postprandial C‐peptide -- Fasting C‐peptide. ACEI, angiotensin converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; GGT, gamma‐glutamyl transferase; HDL, high density lipoprotein; HOMA‐IR, homeostasis model assessment insulin resistance index; hs‐CRP, high sensitivity C‐reactive protein; LDL, low density lipoprotein; NAFLD, non‐alcoholic fatty liver disease; SBP, systolic blood pressure.
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The prevalences of diabetic vascular complications in patients stratified by their NAFLD status are shown in Table [2](#jdi12139-tbl-0002){ref-type="table-wrap"}. The prevalences of diabetic retinopathy and nephropathy were significantly lower in type 2 diabetic patients with NAFLD than in those without NAFLD (33.0 vs 70.2%, *P* \< 0.001; 29.3 vs 37.1%, *P* = 0.007, respectively), whereas no difference was found in the prevalence of diabetic neuropathy. The prevalence of diabetic macrovascular complications was lower in patients with NAFLD than those without NAFLD (9.2 vs 14.7%, *P* = 0.008).

###### Prevalence of diabetic vascular complications according to non‐alcoholic fatty liver disease status

                                                                       Without NAFLD (%)   With NAFLD (%)   *P*‐value
  -------------------------------------------------------------------- ------------------- ---------------- -----------
  Retinopathy                                                                                               
  NPDR                                                                 41.9                21.7             \<0.001
  PDR                                                                  28.3                11.3             
  Neuropathy                                                           50.6                47.2             0.181
  Nephropathy                                                          37.1                29.3             0.007
  Macrovascular complications[a](#jdi12139-note-0002){ref-type="fn"}   14.7                9.2              0.008

Macrovascular complications included coronary artery disease, cerebrovascular disease, and peripheral arterial disease. NAFLD, non‐alcoholic fatty liver disease; NPDR, non‐proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
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After adjustment for confounding factors, such as age, sex, HbA1c, C‐peptide, diabetic duration, BMI and hypertension, NAFLD remained significantly associated with lower OR of diabetic retinopathy (OR 0.440, 95% confidence interval 0.255--0.759, *P *= 0.003) and nephropathy (OR 0.541, 95% confidence interval 0.358--0.817, *P *= 0.003; Table [3](#jdi12139-tbl-0003){ref-type="table-wrap"}). In contrast, after adjustment for confounding factors, NAFLD was not significantly associated with macrovascular complications (Table [3](#jdi12139-tbl-0003){ref-type="table-wrap"}).

###### Odds ratios for vascular complications in type 2 diabetic patients with non‐alcoholic fatty liver disease

                                                                        NAFLD OR (95% CI)      *P*‐value
  --------------------------------------------------------------------- ---------------------- -----------
  Retinopathy                                                                                  
  Model 1                                                               0.402 (0.256--0.561)   \<0.001
  Model 2                                                               0.430 (0.258--0.719)   0.001
  Model 3                                                               0.440 (0.255--0.759)   0.003
  Nephropathy                                                                                  
  Model 1                                                               0.668 (0.475--0.942)   0.021
  Model 2                                                               0.664 (0.455--0.969)   0.034
  Model 3                                                               0.541 (0.358--0.817)   0.003
  Macrovascular complications[\*](#jdi12139-note-0003){ref-type="fn"}                          
  Model 1                                                               0.920 (0.577--1.468)   0.728
  Model 2                                                               1.049 (0.644--1.710)   0.847
  Model 3                                                               0.833 (0.490--1.146)   0.499

Model 1: Adjusted for sex, age. Model 2: Adjusted for sex, age, fasting C‐peptide, glycated hemoglobin, diabetes duration. Model 3: Adjusted for the factors in Model 2 + body mass index, hypertension. \*Macrovascular complications included coronary artery disease, cerebrovascular disease, and peripheral arterial disease. NAFLD, non‐alcoholic fatty liver disease.
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Discussion {#jdi12139-sec-0012}
==========

The present study assessed the relationship of NAFLD with chronic microvascular and macrovascular complications in a cohort of patients with type 2 diabetes. Our major finding was that NAFLD, as diagnosed by characteristic sonographic features, is inversely associated with prevalences of diabetic retinopathy and nephropathy in Korean patients with type 2 diabetes, in contrast to the results of previous studies[11](#jdi12139-bib-0011 jdi12139-bib-0012 jdi12139-bib-0013){ref-type="ref"}. After adjustment for confounding factors, NAFLD remained significantly associated with lower OR of diabetic retinopathy and nephropathy. In contrast, NAFLD was not associated with diabetic neuropathy or macrovascular complications after adjustment for confounding factors.

The association between NAFLD and microvascular complications (retinopathy, nephropathy and neuropathy) in type 2 diabetes has not been studied thoroughly. Three previous studies, two from Italy[11](#jdi12139-bib-0011 jdi12139-bib-0012){ref-type="ref"} and one from Romania[13](#jdi12139-bib-0013){ref-type="ref"}, investigated the association between NAFLD and microvascular complications in type 2 diabetes. Targher *et al*.[11](#jdi12139-bib-0011 jdi12139-bib-0012){ref-type="ref"} showed that NAFLD is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser‐treated retinopathy in patients with type 2 diabetes. Casoinic *et al*.[13](#jdi12139-bib-0013){ref-type="ref"} showed that NAFLD is positively correlated with microalbuminuria, a marker of early‐stage nephropathy in patients with type 2 diabetes. In contrast to these previous studies, the present results showed that NAFLD was inversely associated with prevalences of diabetic retinopathy and nephropathy in Korean patients with type 2 diabetes. This difference in results with previous studies might be related to differences in characteristics of the participants. The present study participants had a lower proportion of men, and lower body mass index, and were younger patients with poorer glycemic control compared with those of the Italian study. Additionally, the patients in the present study underwent a comprehensive assessment for diabetic neuropathy, which has not been assessed in previous studies. In addition, the ethnic differences for pathophysiological characteristics of type 2 diabetic patients could be responsible for the discrepancies between the present results and those of previous studies. In the study by Targher *et al*.[11](#jdi12139-bib-0011){ref-type="ref"}, HbA1c was higher in type 2 diabetes with NAFLD than in those without NAFLD. Thus, insulin resistance associated with NAFLD might have led to poorer glycemic control and a higher prevalence of diabetic complications. In contrast, no significant difference in glycemic control between the two groups was found in the present study. Insulin secretory capacity in Asians, including Koreans, has been proposed to be lower compared with Western subjects[14](#jdi12139-bib-0014 jdi12139-bib-0015 jdi12139-bib-0016 jdi12139-bib-0017){ref-type="ref"}. Higher serum C‐peptide and insulin levels in the present study participants with NAFLD might reflect relatively preserved β‐cell function, which could have beneficial effects on glycemic control, thus decreasing the occurrence of diabetic complications.

Although this cross‐sectional study could not elucidate the potential mechanisms for the inverse association between NAFLD and microvascular complications of diabetes, there are several possible explanations. First, as aforementioned, patients with NAFLD in the present study might have preserved β‐cell function, which leads to more stable glycemic control and a decrease in microvascular complications. Second, we could not exclude the possibility that the shorter duration of diabetes and relatively younger age of patients with NAFLD compared with those without NAFLD might have contributed to a lower prevalence of diabetic complications, even though we adjusted for those factors in logistic regression analysis. In addition, patients with NAFLD, who had higher BMI and insulin resistance, might have encouraged more intensive lifestyle modification, such as diet control and exercise. Therefore, they could have achieved similar glycemic control within a shorter period of time compared with those without NAFLD, which might be related to a lower prevalence of diabetic complications.

The present results showed that serum fasting, postprandial and delta C‐peptide levels were higher in patients with NAFLD than in those without NAFLD. This finding suggested that patients with NAFLD in the present study could have preserved β‐cell function. Unfortunately, we do not have data for a more accurate index of β‐cell function estimated by dynamic tests, such as oral or intravenous glucose tolerance tests or hyperglycemic clamp. However, postprandial 2‐h serum C‐peptide levels are known to be useful indicators of residual β‐cell function in type 2 diabetes patients[18](#jdi12139-bib-0018 jdi12139-bib-0019){ref-type="ref"}, and are closely associated with microvascular complications. Lower serum C‐peptide level was found to be associated with higher prevalences of retinopathy and nephropathy in patients with type 2 diabetes[20](#jdi12139-bib-0020 jdi12139-bib-0021 jdi12139-bib-0022){ref-type="ref"}. In a previous study of patients with type 1 diabetes, residual β‐cell function was reported to be an independent protective factor against the development of microvascular, but not macrovascular, complications[23](#jdi12139-bib-0023){ref-type="ref"}. C‐peptide levels could directly impact the development and/or progression of microvascular complications, as has been shown by others[18](#jdi12139-bib-0018 jdi12139-bib-0019){ref-type="ref"}.

Targher *et al*.[11](#jdi12139-bib-0011){ref-type="ref"} suggested that the possible molecular mediators linking NAFLD with retinopathy and chronic kidney disease (CKD) could include the increased release of some pathogenic mediators from the liver, such as advanced glycation end‐products, reactive oxygen species, CRP, interleukin (IL)‐6 and tumor necrosis factor (TNF)‐α. Several studies have shown that these potential mediators of vascular and/or renal injury are higher in obese and/or diabetic patients with NAFLD than in those without NAFLD[24](#jdi12139-bib-0024 jdi12139-bib-0025 jdi12139-bib-0026 jdi12139-bib-0027){ref-type="ref"}. However, these studies were mostly based on non‐alcoholic steatohepatitis (NASH), and there has been little evidence that inflammatory mediators are increased in patients with simple steatosis. The majority of our study participants with NAFLD might have simple steatosis rather than NASH.

Previous data in some ethnic populations suggested that the presence of NAFLD might increase coronary heart disease risk independent of components of the metabolic syndrome[11](#jdi12139-bib-0011 jdi12139-bib-0028 jdi12139-bib-0029){ref-type="ref"}. Recent data suggest that the presence of NAFLD in type 2 diabetes might also be linked to increased CVD risk independently of components of the metabolic syndrome[6](#jdi12139-bib-0006 jdi12139-bib-0007 jdi12139-bib-0008 jdi12139-bib-0030 jdi12139-bib-0031){ref-type="ref"}. The present our study, NAFLD seemed to be associated with a lower prevalence of CVD in unadjusted analysis. However, after adjustment for confounding factors, NAFLD was not associated with macrovascular complications. Reasons for the discrepancy with previous studies are unclear, but might be related to the lower prevalence of macrovascular complications in our cohort. The present study participants had lower mean BMI, lower prevalence of obesity and lower insulin resistance index compared with the Western populations.

The present study had several limitations. First, this was a cross‐sectional analysis and could not determine causal relationships. Prospective studies are required to confirm the associations between NAFLD and chronic vascular complications of type 2 diabetes. Second, the present study population was a cohort of patients cared for at a single center. Thus, our results might not be generalizable to all patients with type 2 diabetes. However, the majority of our subjects were typical patients with type 2 diabetes commonly encountered in outpatient diabetes clinics. This single‐center study also conferred a high degree of consistency regarding laboratory data, ultrasonographic finding and the evaluation for diabetic complications. Third, the relatively short diabetic duration was a limitation in evaluating the occurrence of chronic diabetic vascular complications.

Despite these limitations, the present results suggest that NAFLD is inversely associated with prevalences of diabetic retinopathy and nephropathy in Korean patients with type 2 diabetes. Furthermore, large‐scale prospective studies are required to elucidate causal associations between NAFLD and the chronic vascular complications of type 2 diabetes.
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